Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St, 20-080, Lublin, Poland.
Curr Oncol Rep. 2024 Nov;26(11):1334-1348. doi: 10.1007/s11912-024-01589-4. Epub 2024 Aug 7.
This document critically examines the role of cannabinoids in cancer care during an era marked by rapid advancements in oncology and changing perceptions on cannabis. It traces the historical context of cannabis in medicinal use, navigating its journey from widespread acceptance, subsequent criminalization, to its resurgence in modern therapeutic applications, particularly within the framework of Evidence-Based Medicine (EBM).
Anchored in EBM principles, this study synthesizes current research from clinical trials, systematic reviews, and meta-analyses to evaluate the efficacy and safety of cannabinoids in oncology. The focus is on their palliative effects, considering the nuances of effectiveness, risk assessment, and challenges inherent in translating these findings into clinical guidelines. The study seeks to bridge the gap between scientific research and clinical practice, offering insights to inform future oncological therapies and symptom management strategies involving cannabinoids. The potential benefits and risks of cannabinoid use in cancer treatment are assessed to guide clinicians and researchers in developing comprehensive, evidence-based approaches to patient care.
本文批判性地审视了在肿瘤学快速发展和对大麻认知不断变化的时代背景下,大麻素在癌症治疗中的作用。本文追溯了大麻在医学应用中的历史背景,探讨了它从广泛接受、随后的刑事定罪到在现代治疗应用中复兴的历程,特别是在循证医学(EBM)框架内。
本研究以循证医学原则为基础,综合了来自临床试验、系统评价和荟萃分析的最新研究,评估了大麻素在肿瘤学中的疗效和安全性。重点关注其姑息治疗效果,考虑到有效性、风险评估的细微差别,以及将这些发现转化为临床指南所固有的挑战。本研究旨在弥合科学研究与临床实践之间的差距,为未来涉及大麻素的肿瘤治疗和症状管理策略提供信息,以指导临床医生和研究人员制定全面、基于证据的患者护理方法。评估大麻素在癌症治疗中的潜在益处和风险,以指导临床医生和研究人员制定全面、基于证据的患者护理方法。